2 hrs ago. The US Food and Drug Administration wi
Post# of 152116

Bloomberg.
_____
While we're developing stunningly safe versions of Long acting Leronlimab. Without billions in development costs & high corporare overhead costs.
Now we'll have data to Vs. a vaccine.
Our NASH/MASH protocol mentions West Nile virus & CCR5.
Zika is mentioned in our FcRn abstract. To name a couple potentials.

